rethinkTHC Search
Menu
Study breakdown

Cannabis and Inflammatory Bowel Disease in Children: What Pediatric Doctors Need to Know

Narrative ReviewModerate evidence
The takeaway

As cannabis legalization spreads, pediatric IBD specialists face growing patient interest in cannabis, but evidence for benefits remains limited while developmental risks for young users are concerning.

Read this if you are a parent or caregiver of a child with IBD who is curious about cannabis as a treatment option.

Federal legal barriers significantly hamper research on cannabis for pediatric IBD

What the researchers found

Writing from Colorado, one of the first states to legalize recreational cannabis, pediatric gastroenterologists described the practical reality of caring for children and adolescents with IBD in an environment of increasing cannabis awareness and acceptance.

The review outlined the endocannabinoid system's role in gastrointestinal function, noting biological plausibility for both beneficial and harmful effects of cannabis in IBD. Cannabis could potentially reduce inflammation and symptoms, but could also impair developing brains and interact with other treatments.

Public perception of cannabis safety had outpaced the evidence, particularly for pediatric populations. The authors noted that federal legal barriers significantly hampered research efforts, making it difficult to generate the evidence needed to guide clinical decisions.

The review emphasized that pediatric gastroenterologists need to understand the cannabis landscape and be prepared to discuss it openly with patients and families, even without definitive evidence.

Why it matters

This is one of the few reviews addressing cannabis and IBD specifically in pediatric populations. Children and adolescents with IBD face a unique risk-benefit calculus: potential symptom relief versus developmental risks during critical brain maturation periods.

The numbers in context

Colorado legalized medical cannabis in 2000 and recreational cannabis in 2012. The review does not report specific clinical outcome data.

How the study worked

Narrative review describing the legalization landscape in Colorado, the endocannabinoid system's relevance to IBD, clinical experience with pediatric IBD patients, and research barriers created by federal cannabis scheduling.

What this study cannot tell us

Primarily a perspective piece from a single institution in Colorado rather than a systematic evidence review. No original clinical data are presented. The pediatric-specific evidence for cannabis in IBD is extremely limited.

How to read the evidence

Narrative clinical perspective from experienced pediatric gastroenterologists. Moderate because it draws on legitimate clinical experience and existing literature but presents no original data.

When this study was published

Published in 2017, reflecting the early legal cannabis era in Colorado.

The bigger picture

This review captures a transitional moment in cannabis medicine where clinical reality (patients already using cannabis) is ahead of research evidence (insufficient data to guide recommendations). The tension between patient demand and evidence gaps is especially acute in pediatric care.

Questions still open

  • Could CBD-only preparations offer anti-inflammatory benefits for pediatric IBD without THC-related developmental risks? Have changes in federal research policies since 2017 improved the ability to study cannabis in children? What are pediatric IBD patients actually using in legalized states?

Common questions

Should children with IBD use cannabis?
This review does not recommend it. While there is biological plausibility for benefits, the evidence is insufficient to guide treatment in pediatric populations, and developmental risks during brain maturation add additional concern.
Why is it hard to study cannabis for children's diseases?
Federal classification of cannabis as a Schedule I substance creates significant barriers to research, including limited access to standardized products and complex approval processes. This is especially challenging for pediatric research, which requires additional protections.

Read the original research

Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.

Journal of pediatric gastroenterology and nutrition, 64(2), 265-271

Citation

Hoffenberg, Edward J; Newman, Heike; Collins, Colm; Tarbell, Sally; Leinwand, Kristina. (2017). Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.. Journal of pediatric gastroenterology and nutrition, 64(2), 265-271. https://doi.org/10.1097/MPG.0000000000001393

Explore the wider topic